Second-Line Treatment Landscape for Renal Cell Carcinoma: A Comprehensive Review

The Oncologist
Nizar M TannirM B Atkins

Abstract

The management of advanced clear-cell renal cell carcinoma has steadily improved over the past decade with the introduction of antiangiogenic and targeted therapies. Recently, three new therapies have been approved for use as second-line options that further advance the treatment armamentarium: nivolumab, a monoclonal antibody targeting the programmed cell death receptor; cabozantinib, a small-molecule tyrosine kinase inhibitor (TKI) of vascular endothelial growth factor receptor (VEGFR), MET, and AXL; and lenvatinib, a small-molecule TKI of VEGF and fibroblast growth factor receptors that is used in combination with everolimus, an inhibitor of the mechanistic target of rapamycin. Together, these and previously approved second-line treatments offer clinicians the ability to better individualize treatment for patients after progression on first-line VEGFR-targeted therapies. In this comprehensive review, we discuss the efficacy and safety results from the pivotal trials of these newly approved therapies, including the quality of study design, the level of evidence, subgroup analyses, and how these data can help to guide clinicians to select the most appropriate second-line therapy for their patients. This review article provides...Continue Reading

References

Nov 10, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Brian I Rini, Eric J Small
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Feb 24, 2009·The American Journal of Cardiology·Rahul SakhujaDeepak L Bhatt
Mar 10, 2009·Lancet·Brian I RiniBernard Escudier
Jul 2, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anna GustafssonBjörn Dahlbäck
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Mar 13, 2010·The Journal of Pathology·Marcella M BaldewijnsAdriaan P de Bruïne
Sep 15, 2010·International Journal of Cancer. Journal International Du Cancer·Ingrid M E DesarI Jolanda J M de Vries
Dec 1, 2011·Therapeutic Advances in Medical Oncology·Shawna Leslie Organ, Ming-Sound Tsao
Jan 3, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E CalvoR A Figlin
Jul 19, 2012·Neoplasia : an International Journal for Oncology Research·Gunther BoysenHolger Moch
Oct 2, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G T GibneyH M Kluger
Apr 30, 2013·The Journal of Biological Chemistry·Franziska StehleBarbara Seliger
Jun 25, 2013·Nature·UNKNOWN Cancer Genome Atlas Research Network
Dec 3, 2014·Trends in Molecular Medicine·Kim C OhaegbulamXingxing Zang
May 7, 2015·Journal of Diabetes Research·Borja QuirogaGabriel de Arriba
May 28, 2015·Cancer Immunology Research·Marcella CalleaSabina Signoretti
Sep 1, 2013·EJC Supplements : EJC : Official Journal of EORTC, European Organization for Research and Treatment of Cancer ... [et Al.]·Rosalie Fisher, James Larkin
Sep 9, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Laurence AlbigesToni K Choueiri
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 26, 2015·The New England Journal of Medicine·Toni K ChoueiriUNKNOWN METEOR Investigators
Oct 23, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J WagstaffS Buchan

❮ Previous
Next ❯

Citations

Dec 7, 2018·Cancers·Estíbaliz López-Fernández, José I López
Feb 21, 2019·Medical Oncology·José Luis Pérez-GraciaCristina Suárez
Jul 6, 2020·Cancer Immunology, Immunotherapy : CII·Gigja GudbrandsdottirChristian Beisland
Aug 9, 2020·Medical Oncology·Gianluca PeregoFausto Petrelli
Sep 16, 2020·Expert Review of Anticancer Therapy·Ehab AbdouEnrique Grande
Sep 4, 2020·World Journal of Clinical Oncology·Viraj V KhetaniEric A Singer
Feb 3, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Swapnil P BhujbalSeung Joo Cho
Sep 30, 2021·Journal of Experimental & Clinical Cancer Research : CR·Weipu MaoMing Chen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.